Our look is new. Our purpose is the same. Learn more about our brand evolution.
FSHD Society co-founder knew the stakes were high to get things right by Daniel Paul Perez, co-founder FSHD Society Bill Michael William G. “Bill” Michael passed peacefully at the […]
[…] “consistent” reductions in DUX4 activity along with improvements in strength and function by June Kinoshita, FSHD Society Avidity Biosciences, Inc., a San Diego-based biopharmaceutical company, announced this Wednesday, June 12, […]
[…] new era in clinical trials, what do we mean? After all, we have seen previous FSHD trials, including those by Wyeth, aTyr, Acceleron, and Fulcrum’s ReDUX4. What makes the current […]
[…] media spotlight last week after publication of their paper on the application of CRISPR technology in FSHD cells. In response to the public’s interest in the story, they prepared the following […]
The FSHD Society is holding a landmark meeting today in which individuals and families living with facioscapulohumeral muscular dystrophy (FSHD) will tell representatives from the U.S. Food and Drug Administration […]
